Swissmedic grants conditional marketing authorisation to Nuvaxovid
The vaccine, also known as NVX-CoV2373, is the first protein-based vaccine to be authorised for use in Switzerland
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.